Company ProfilePremium

Abbott India Limited

Company Profile Analysis

Tickers: ABBOTINDIA.NS, 500488.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Abbott India Limited - Company showcase

Year Founded & Workforce

1944

3,679 Employees

Abbott India Limited logo

Abbott India Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Abbott India Limited Overview

Abbott India Limited is the listed Indian pharmaceutical subsidiary of Abbott Laboratories and one of the most profitable multinational pharma franchises in the Indian Pharmaceutical Market (IPM). It markets a branded-generics portfolio of roughly 140+ brands concentrated in gastroenterology, women's health, metabolics (thyroid and diabetes), central nervous system (vertigo, sleep, depression), multi-specialty (vitamin D, pain) and vaccines, and it also earns distribution margins on in-licensed brands from Novo Nordisk (insulins, oral and injectable semaglutide) and Abbott Healthcare Pvt Ltd. Its moat rests on category-leading heritage brands — Thyronorm, Udiliv, Duphalac, Cremaffin, Digene, Duphaston, Vertin, Creon, Influvac — that hold #1 or #2 positions in their sub-segments, a highly productive field force, an asset-light manufacturing model (one owned plant in Goa plus third-party manufacturing), zero financial debt and a ~90% dividend payout. FY2026 revenue was ₹6,929 Cr with a 22.4% net margin and ~34.5% return on average equity.


Company's own description (paraphrased from Annual Report FY2025-26)

The Annual Report describes Abbott India as a company that has been advancing health in India for more than eight decades by combining Abbott's global scientific expertise with trusted brands and local market understanding. It names its core therapy areas as Gastrointestinal, Women's Health, Metabolics, CNS, Vaccines and Multi-Specialty, and describes its strategy as expanding into differentiated therapies and preventive healthcare, executed through a digitally enabled sales organisation, deep physician/specialist relationships and operational excellence. The investment-case page frames the "next phase of growth" around expanding access in high-burden, under-penetrated therapy areas (cardiometabolic, liver disease including MASLD/MASH, CNS and adult immunisation), building integrated multi-franchise platforms across the continuum of care, and pursuing a "build and partner" approach that combines organic brand building with selective partnerships and acquisitions.

Independent characterisation

Abbott India is, economically, a brand-owning marketing and distribution company with light manufacturing. Its value creation lies in (a) owning or exclusively commercialising prescription brands that physicians habitually prescribe, (b) a large, trained medical-representative ("Therapy Business Manager") force that details ~250,000 healthcare professionals (≈13,000 CME programmes in FY2026), and (c) a supply chain that leans on third-party and affiliate manufacturing, with its single owned plant at Goa producing tablets and liquids (FY2026 incremental production: 1,338.72 MT tablets; 7,311.91 kL liquids).

Business model and revenue model

DimensionCharacterisation
Revenue model~100% product sales (branded formulations); no subscription or material licensing revenue disclosed
Own brands vs in-licensedOwn/Abbott-group brands form the core; a material layer of revenue comes from distributing Novo Nordisk products (Human Mixtard, Novomix, Ryzodeg, Rybelsus; Extensior from 2026; Awiqli from mid-2026) and certain Abbott Healthcare Pvt Ltd brands on which Abbott India earns a distribution margin. Exact split not publicly disclosed
Value-chain positionDownstream: brand ownership, medical promotion, regulatory, distribution. Limited upstream manufacturing (Goa)
Customers (direct)Independent distributors / stockists; institutional channels (corporate hospitals, specialty networks) being expanded
Customers (demand drivers)Physicians (gastroenterologists, gynaecologists, endocrinologists/diabetologists, consulting physicians, ENT/neurologists, orthopaedics) and, for OTC-adjacent brands (Digene), consumers
End-marketsIndian domestic prescription market (IPM) overwhelmingly; a small international business is housed under the Women's Health/Metabolics commercial director
Pricing environmentRegulated: a subset of products falls under the Drug Price Control Order / National List of Essential Medicines (NPPA ceilings); non-scheduled products limited to ~10% annual price increases
ChannelProducts are sold through independent distributors primarily within India (company description in filings)

End-markets served (therapy lens)

Per Pharmarack MAT July 2026 data cited by BOB Capital Markets (3 Sept 2026), Abbott India's secondary-market sales were ≈₹5,000 Cr (+10% YoY), of which gastro ≈46% (≈₹2,300 Cr) and women's health ≈10% (≈₹492 Cr, +8%). Note that secondary-market (retail audit) values differ from reported revenue (which is net of trade margins and includes distribution arrangements).

Strategy

Stated strategy (paraphrased themes, AR FY2025-26)

  1. Sustained market-beating growth in therapy areas and brands with durable demand.

  2. Building and sustaining large brands valued by physicians and patients.

  3. Therapy-area relevance: chronic/sub-chronic care, preventive health and adult vaccination, metabolic disorders, women's health, GI/liver and CNS.

  4. Productivity and profitability: balance growth investment with cost discipline and sustainable margin thresholds.

  5. Build and partner: organic development and lifecycle management plus selective partnerships and potential acquisitions to enter adjacencies.

  6. Go-to-market evolution: institutional channels, corporate hospitals, specialty networks; digital and analytics; Tier 2/3 expansion.

  7. People: internal succession (all leadership appointments in FY2026 filled internally; attrition declined).

The MD's letter sets an aspiration of "market-aligned growth" with continued profitability improvement; the business model page lists five Abbott-wide sustainability priorities (healthy environment; innovation for access and affordability; diverse workforce; resilient supply chain; responsible use of data and technology).

Strategic initiatives — last 24 months

DateInitiativeTypeDetail / intent
Jun 2025Leadership transition to Kartik RajendranLeadershipSpecialty-care and SE Asia commercial background
FY2026Field-force build-out (345+ TBMs onboarded; 150,000+ person-hours of frontline training)CapabilitySupports GLP-1 and new launches
FY2026Five new product launches incl. Duphalac Rapid, Combinorm Plus, Digene Insta On The GoLifecycleLeverage brand equity
FY2026SKU rationalisation in Multi-SpecialtyCost/portfolioImprove productivity
FY2026Vaccine sourcing/supply-chain streamliningOperationsPeak-season reliability
27 Feb 2026Extensior (semaglutide) with Novo Nordisk IndiaPartnershipGLP-1 entry beyond Novo's own reach
Jul–Aug 2026Awiqli once-weekly insulin distributionPartnershipPartially offsets Mixtard phase-out
FY2026–27Women's Health diversification into fertility, contraception, menopausePortfolioReduce dydrogesterone dependence
FY2026–27Adult immunisation expansion beyond metrosMarket accessUnder-penetrated category
FY2026~90% payout incl. ₹131 special dividendCapital allocationReturn surplus cash
OngoingCSR: PHC upgrades (209 cumulative), NCD-nutrition programme designESGAccess to care

Cost programmes with targets: none with quantified targets disclosed. Medium-term financial targets/guidance: none disclosed; management targets market-aligned growth and margin resilience.

Products & Services

Abbott India markets 140+ brands (ICICI Securities). Seven brands are in the IPM top 100 and ten in the top 300 (IQVIA MAT March 2026, per AR). Pricing is regulated or MRP-based; individual brand MRPs are not tabulated by the company.

Gastrointestinal

BrandMolecule / descriptionIndicationTarget prescriberStatus / data points
UdilivUrsodeoxycholic acidCholestatic liver disease, gallstones, hepatoprotectionGastroenterologists, physicians#1 hepatoprotective brand; crossed ₹700 Cr (AR FY2026); MAT ≈₹712 Cr, ~52% market share (ICICI/BOB 2025)
DuphalacLactuloseConstipation, hepatic encephalopathyPhysicians, gastroenterologistsTop-10 brand; Duphalac Rapid launched FY2026
Cremaffin / Cremaffin PlusLiquid paraffin + milk of magnesia (+ sodium picosulfate in Plus)ConstipationPhysiciansLeadership in laxatives
DigeneAntacid/antiflatulent (multiple formats)Acidity, gasConsumers, physicians#ControlKar campaign reached 44 million consumers; brand awareness 96%; Digene Insta On The Go (tear-and-sip; orange flavour launched FY2026) won two Gold and one Silver at afaqs! Digies
CreonPancrelipase (pancreatin)Exocrine pancreatic insufficiencyGastroenterologistsGlobal Abbott brand under further development (AR)
GanatonItoprideFunctional dyspepsia / GI motilityPhysicians, gastroenterologistsCrossed ₹100 Cr in FY2026
ColospaMebeverineIrritable bowel syndromeGastroenterologistsRanks in top of respective market (AR)
LibraxChlordiazepoxide + clidiniumIBSGastroenterologistsTop brand in RPM (AR)
HeptralAdemetionineLiver diseaseHepatologistsListed among top brands (AR)
PankreoflatPancreatin + dimethiconeIndigestion/flatulencePhysiciansLegacy brand
VonefiLaunch FY2026Acid-related disorders (GI)GastroenterologistsNew launch
DigeraftLaunch FY2026GI (antacid/reflux segment)PhysiciansListed among top brands in RPM

Metabolics (own and in-licensed)

BrandMolecule / descriptionIndicationOwnershipData points
ThyronormLevothyroxine sodium (multiple strengths)HypothyroidismOwn#1 in hormones; MAT ≈₹716 Cr; ~55.6% share (ICICI/BOB); #LiveThyronormal awareness campaign
Combinorm PlusLaunch FY2026MetabolicOwnNew launch
ExtensiorSemaglutide injection (second brand of Ozempic), manufactured by Novo NordiskType 2 diabetes (adjunct to diet/exercise)Exclusive commercialisation for Novo Nordisk India (Feb 2026)Pricing not publicly disclosed
Human MixtardPremixed human insulinDiabetesNovo Nordisk (distributed)≈₹795 Cr MAT Jan 2026, #5 brand in IPM (Pharmarack); being phased out by Novo
NovomixBiphasic insulin aspartDiabetesNovo Nordisk (distributed)Declined in Q3 FY2026 (ICICI)
RyzodegInsulin degludec + insulin aspartDiabetesNovo Nordisk (distributed)Growing; improved IPM rank in May 2026 (Equirus)
RybelsusOral semaglutideType 2 diabetesNovo Nordisk (distributed)≈₹400 Cr MAT May 2025, 173% 3-year CAGR (BOB, July 2025)
AwiqliInsulin icodec, once-weekly basal insulinType 1 and Type 2 diabetesNovo Nordisk (Abbott distribution confirmed Aug 2026)₹261/week for 70 units; 1 mL pen (700 units) MRP ₹2,611; 3 mL pen ₹7,833

Women's Health

BrandMoleculeIndicationData points
DuphastonDydrogesteroneThreatened/recurrent miscarriage, luteal support in IVF, progesterone deficiencyCategory leader; "She Deserves Duphaston" campaign; ESHRE-guideline-aligned programme; facing lower-priced generics
FemostonEstradiol + dydrogesteroneMenopausal hormone therapy"Fearless Tomorrow" menopause awareness
DuvadilanIsoxsuprinePre-term labourTop brand in RPM
FemilonDesogestrel + ethinylestradiolContraception+3% / +14% in recent periods (BOB table)
NovelonDesogestrel + ethinylestradiolContraception—

Central Nervous System

BrandMoleculeIndicationData points
VertinBetahistineVertigo (incl. BPPV, Ménière's)≈₹396 Cr MAT Jan 2026, +18.1% value growth (Pharmarack)
ProthiadenDothiepin (dosulepin)Depression, painTop brand in RPM
InderalPropranololMigraine prophylaxis, anxiety, hypertensionLegacy brand
ZolfreshZolpidemInsomniaTop brand in RPM
EptoinPhenytoinEpilepsyLegacy brand (company fact sheet)

Multi-Specialty

BrandMoleculeIndicationData points
Arachitol / Arachitol NanoCholecalciferol (vitamin D3), nano-formulationVitamin D deficiencyDriver of segment growth; D-STRONG ACTIVE LIFE screened 70,000+ individuals
Arachitol InjectionCholecalciferol injectionVitamin D deficiency—
Brufen / Brufen PIbuprofen; ibuprofen + paracetamolPain, feverLegacy brand
EzybixyLaunch FY2026 (therapy/composition not disclosed in sources reviewed)—New launch

Vaccines

BrandDescriptionIndicationData points
InfluvacInactivated influenza vaccine (manufactured by Abbott group)Influenza prevention (adult, maternal, paediatric)Among IPM top-50 brands; FOGSI partnership for antenatal flu vaccination
Pneumoshield 1414-valent pneumococcal vaccinePneumococcal diseaseSupported by Pneumoserve long-term study
HavshieldHepatitis A vaccineHepatitis A—
Typhoid and Japanese encephalitis vaccinesBrands not named in sources reviewed—Part of preventive portfolio

FY2026 new launches (AR)

Duphalac Rapid; Extensior; Ezybixy; Combinorm Plus; Digene Insta On The Go (Orange). Additional GI launches discussed: Vonefi, Digeraft. Five "new products launched" are counted in AR outputs. Company track record: >100 product launches over 12 years (ICICI Securities); 7 new brands in FY2025 (incl. Citrosoda UTI).

Services

No paid services. "Beyond the pill" patient-support and screening programmes (thyroid, liver, vitamin D screening; 14.08 lakh screenings via health clinics in CSR programmes) support brand franchises but are not monetised.

Financial Narrative

All figures standalone Ind AS, ₹ Cr, fiscal years ending 31 March. Source: Annual Report FY2025-26 (10-year highlights) unless noted. Abbott India has no subsidiaries; standalone = company.

Income statement

FY2021 base for CAGR: revenue ₹4,310 Cr; PAT ₹691 Cr.

Margins and growth

CAGRs (computed): Revenue FY2021–26 (5-year) 9.9%; FY2022–26 (4-year) 9.0%. PAT FY2022–26 18.1%. EBITDA (incl. OI) FY2022–26 16.9%. The Annual Report states 10-year CAGRs of 9.0% (revenue), 17.0% (EBITDA), 18.8% (PAT) and 18.8% (share price).

Commentary. The defining feature of the last five years is margin expansion outpacing a high-single-digit top line. Revenue compounded at ~9%, broadly in line with the IPM, while PAT compounded at ~18%. Three drivers stand out. First, operating leverage on fixed costs: employee expense was virtually flat from FY2022 (₹579 Cr) to FY2025 (₹588 Cr) while revenue rose 30%, and other expenses rose only ~6% over the same period. Second, mix: own high-margin brands (Udiliv, Thyronorm, Cremaffin, Vertin) outgrew the low-margin distributed insulin portfolio, lifting gross margin to 46.7% in FY2026. Third, other income tripled from ₹83 Cr to ₹288 Cr as the cash pile grew and yields rose; other income was ~14% of PBT in FY2026.

FY2026 shows an inflection in cost growth: employee cost jumped 13.8% (₹588 Cr → ₹669 Cr), reflecting the Labour Code accrual (₹18.10 Cr), field-force additions (345+ new TBMs onboarded) and, per BOB Capital (Feb 2026), preparation for the GLP-1 launch. Finance cost more than doubled to ₹25 Cr due to Ind AS 116 lease accounting (likely the new BKC corporate office lease — inference), cutting interest coverage from 166x to 84x, though this is non-economic for a debt-free company. Revenue growth slowed to 8.1%, below the IPM's ~8–10% in CY2025–26, which brokers attribute to the Novo Mixtard phase-out (BOB, May 2026).

Quarterly trajectory

Q3 FY2026 revenue and PAT are computed as balancing figures (full year less other quarters); Q3/Q4 EPS computed on 21,249,302 shares. Q1 FY2027: revenue +4.3% YoY, PBT ₹572.21 Cr (+16.0%), PAT +17.1%, EBITDA margin 28.81% vs 25.63% (company results; margin per results commentary). Total income ₹1,889.05 Cr; total expenses ₹1,316.84 Cr. Q4 FY2026: revenue +6.5%, PAT +7.6%, operating profit +12.2% to ₹480.85 Cr.

Q2 FY2027 (quarter ended 30 Sep 2026) results are pending; trading window closed from 1 Oct 2026; statutory deadline 14 Nov 2026; board-meeting date not yet disclosed in sources reviewed.

Balance sheet

Sources: Equity, reserves, BVPS — AR FY2025-26. Cash/investment, inventory, receivable, PP&E lines — stockanalysis.com (derived from company filings; converted from INR millions). Discrepancy: BOB Capital Markets cites "cash and bank balance" of ₹2,250 Cr in FY2026 (vs ₹1,630 Cr FY2025), a narrower definition that excludes certain deposits/investments; stockanalysis classifies ₹2,178 Cr as long-term investments. Readers should treat ₹2,250–4,410 Cr as the range depending on definition.

Lease liabilities (only "debt"): AR debt-equity ratio (lease liabilities ÷ equity) of 0.05x (FY2025) and 0.04x (FY2026) implies lease liabilities of roughly ₹212 Cr and ₹191 Cr (computed).

Working capital (FY2025–26 only): Current ratio 3.37x → 2.55x (AR). Using aggregator current assets (₹4,763 Cr FY2025; ₹3,771 Cr FY2026), implied net working capital is ≈₹3,350 Cr → ≈₹2,290 Cr (computed); the decline reflects reclassification of deposits from current to non-current, not operating deterioration.

Cash flow

Sources: OCF FY2025–26 from audited cash-flow statement (₹1,011.84 Cr; ₹1,319.24 Cr); earlier years and capex/FCF from stockanalysis.com. Discrepancies: (1) the AR KPI page shows FY2025 cash generated from operations as ₹1,024 Cr versus ₹1,011.84 Cr in the audited cash-flow statement; (2) screener.in shows FY2026 FCF of ₹1,307 Cr vs ₹1,278 Cr computed above.

Commentary. Cash conversion is structurally strong (5-year cumulative FCF ≈₹5,165 Cr vs cumulative PAT ≈₹5,915 Cr; ~87%), with capex consistently <1% of revenue. FY2025 was the weak year (OCF −17%) because inventory jumped ₹262 Cr (₹620 Cr → ₹882 Cr) and other receivables rose; FY2026 OCF recovered 30% to ₹1,319 Cr despite inventory days rising to 90.4 from 78.3. Effectively all FCF is distributed; the FY2026 ₹656 dividend implies a cash outflow of ≈₹1,394 Cr in FY2027 — above FY2026 FCF — funded from the cash pile.

Ratios

Note: AR labels PAT ÷ average capital employed as "RoCE" (29.5/31.6/34.9/35.7/34.5%); for a debt-free company this equals ROE. AR "Return on Net Worth" is 35.66% (FY2025) and 34.46% (FY2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Pharmaceuticals segment revenue (INR Cr)

5,8496,4096,929

Segment profit before tax (INR Cr)

1,6181,8872,079

PBT margin (%)

27.729.430.0

Revenue YoY growth (%)

9.49.68.1

Contribution to total revenue (%)

100100100

Segment Revenue

DivisionProducts (flagship)FY2026 performance commentary (AR FY2025-26)Market rank (IQVIA MAT Mar 2026)

Gastrointestinal

Udiliv, Duphalac, Cremaffin/Cremaffin Plus, Digene, Creon, Ganaton, Colospa, Librax, Heptral, Vonefi, Digeraft

Robust double-digit growth, significantly ahead of market; Udiliv crossed ₹700 Cr; Ganaton became 7th GI brand above ₹100 Cr

#4 in GI; #1 in hepatoprotectives

Metabolics

Thyronorm, Combinorm Plus, Extensior; distributed Novo insulins/Rybelsus/Awiqli

Thyronorm sustained leadership; Extensior marked GLP-1 entry

#1 in hormones

Women's Health

Duphaston, Femoston, Duvadilan, Femilon, Novelon

Resilient despite dydrogesterone generic price pressure; diversification into fertility, contraception, menopause

#4 in gynaecology

CNS

Vertin, Prothiaden, Inderal, Zolfresh

Consistent growth led by Vertin in vertigo

#4 in CNS

Multi-Specialty

Arachitol (Nano, injection), Brufen

Strong growth led by Arachitol nano-formulation; SKU rationalisation

—

Vaccines

Influvac, Pneumoshield 14, Havshield, typhoid and JE vaccines

Stable; trivalent/quadrivalent influenza transition intensified pricing pressure

#4 in vaccines

“—” = not publicly disclosed.

Therapy Details

Therapy (MAT July 2026)Sales (INR Cr)YoY growth (%)Share of Abbott India secondary sales (%)

Gastrointestinal

2,300

not stated

46

Women's Health

492810

Total Abbott India (secondary)

5,00010100

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

4,9135,3495,8496,4096,929

Other income (INR Cr)

83154248276288

Material cost (INR Cr)

2,6572,9753,2203,4973,693

Gross profit (INR Cr, computed)

2,2562,3742,6292,9123,236

Employee benefit expense (INR Cr)

579564577588669

Other expenses (INR Cr)

595604599630675

EBITDA incl. other income (INR Cr, company definition)

1,1651,3601,7011,9702,180

EBITDA excl. other income (INR Cr, computed)

1,0821,2061,4531,6941,892

Depreciation & amortisation (INR Cr)

6670717276

Operating income / EBIT excl. other income (INR Cr, computed)

1,0161,1361,3821,6221,816

Finance cost (INR Cr)

1916121125

Profit before tax (INR Cr)

1,0801,2741,6181,8872,079

Tax (INR Cr)

281325417473527

Net income (INR Cr)

7999491,2011,4141,552

EPS basic = diluted (INR)

375.86446.78565.28665.62730.36

Dividend per share incl. special (INR)

275325410475656

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth (%)

14.08.99.49.68.1

Gross margin (%)

45.944.444.945.446.7

EBITDA margin incl. OI (%, company)

23.725.429.130.731.5

EBITDA margin excl. OI (%)

22.022.524.826.427.3

Operating margin excl. OI (%)

20.721.223.625.326.2

PBT margin (%)

22.023.827.729.430.0

Net margin (%)

16.317.720.522.122.4

Effective tax rate (%)

26.025.525.825.125.3

Dividend payout (%)

73.272.772.571.489.8

Income Statement and Per-Share Data (Quarterly)

MetricQ1FY2026Q2FY2026Q3FY2026Q4FY2026Q1FY2027

Revenue from operations (INR Cr)

1,738.351,757.151,724.041,709.511,813.68

Net profit (INR Cr)

365.86415.27375.96394.93428.52

EPS (INR)

172.17195.42176.93185.85201.66

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total equity (INR Cr)

2,8203,1893,6994,2334,774

Share capital (INR Cr)

2121212121

Reserves & surplus (INR Cr)

2,7993,1683,6784,2124,753

Book value per share (INR)

1,3271,5011,7411,9922,247

Cash & cash equivalents (INR Cr)

133240292561442

Current investments & bank deposits (INR Cr)

2,6031,6831,8262,5531,790

Non-current deposits/investments (INR Cr)

01,1371,5066722,178

Total cash, deposits & investments (INR Cr)

2,7353,0593,6243,7854,410

Bank borrowings (INR Cr)

00000

Net debt excl. leases (INR Cr)

-2,735-3,059-3,624-3,785-4,410

Inventory (INR Cr)

688649620882947

Trade receivables (INR Cr)

288319319380362

Property, plant & equipment incl. ROU (INR Cr)

263233228348333

Goodwill (INR Cr)

00000

Other intangibles (INR Cr)

8.67.56.76.53.8

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

9488931,2131,0121,319

Capital expenditure (INR Cr, computed)

4434485341

Free cash flow (INR Cr)

9048591,1659591,278

Dividends paid (INR Cr, computed from DPS paid in year)

5845846918711,009

Share buybacks (INR Cr)

00000

Investing cash flow (INR Cr)

-396-148-416182-371

Financing cash flow (INR Cr)

-637-639-745-925-1,066

FCF / net income (%)

11391976882

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE — PAT on average equity (%)

29.531.634.935.734.5

Pre-tax return on average equity (%, computed)

39.842.447.047.646.2

Debt (leases) to equity (x)

0.00.00.00.050.04

Cash conversion cycle (days, screener.in)

-6-8-2433

Working Capital (Days) and Financial Ratios (x)

Ratio (two-year, AR FY2025-26)FY2025FY2026

Debtor days

19.9119.54

Inventory days

78.3390.40

Interest coverage (x)

166.0984.20

Current ratio (x)

3.372.55

Operating profit margin incl. OI, EBIT basis (%)

29.6030.37

Revenue by Region and Region Margins & Growth (%)

MetricFY2024FY2025FY2026

Revenue from operations, all geographies (INR Cr)

5,8496,4096,929

YoY growth (%)

9.49.68.1

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 31 March (INR)

17,69922,08726,94630,73125,923

Market capitalisation (INR Cr)

37,61046,93257,25865,30055,085

Dividend per share (INR)

275325410475656

EPS (INR)

375.86446.78565.28665.62730.36

P/E at year-end (x, computed)

47.149.447.746.235.5

Share Price & Returns

HorizonReturnBasis

1 year

≈ −12%

to 15 Oct 2026 (Kotak data)

3 years

≈ +14% cumulative

to 27 Aug 2026 (Anand Rathi data)

Since 31 Mar 2022 (~4.5 years)

≈ +48%

₹17,699 → ₹26,170 (computed)

10-year CAGR

18.8%

to 31 Mar 2026 (AR)

52-week range

₹25,135 – ₹30,655

as of 15 Oct 2026

Last close

₹26,170

16 Oct 2026

Valuation Multiples

MultipleAbbott IndiaBasis

P/E (TTM EPS ₹759.85)

34.4x

FY2026 EPS + Q1 FY2027 − Q1 FY2026

P/B (BVPS ₹2,247)

11.6x

March 2026 book

EV/EBITDA (TTM EBITDA incl. OI ≈₹2,257 Cr; EV ≈₹53,360 Cr using ₹2,250 Cr cash)

≈23.6x

Computed; ≈22.7x if ₹4,410 Cr cash/investments deducted

EV/Sales (TTM revenue ≈₹7,004 Cr)

≈7.6x

Computed

Dividend yield (₹656)

≈2.5%

Includes special dividend

Analyst Ratings & Targets

BrokerDateRatingTarget (INR)Thesis

BOB Capital Markets

13 May 2026

BUY

36,457

40%+ ROCE, cash optionality; PAT CAGR moderated by Mixtard phase-out

ICICI Securities

13 Feb 2026

BUY

32,150

35x FY2028E EPS ₹918.4

ICICI Securities

13 Aug 2026

(BUY, per secondary report)

32,210

Post-Q1 update

Unnamed brokerage

11 May 2026

Double downgrade

—

Weak growth outlook (headline only)

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance

No numerical guidance. Management targets market-aligned growth, continued margin improvement through mix and productivity, scaling Extensior, above-market growth in GI, double-digit growth in Multi-Specialty, and expansion in adult vaccines and women's health adjacencies (AR FY2025-26, divisional outlooks for FY2026-27).

Consensus-type expectations (broker models)

ICICI Securities models revenue growth of ~9–10% and PAT growth of ~9–13% over FY2026E–FY2028E with EBITDA margins ~27–28% (excl. OI basis); BOB Capital expects EPS growth of ~10–12% annually. Q1 FY2027 delivered profit growth (+17%) ahead of these trends but revenue growth (+4.3%) below them.

Bull case

  1. Mix-driven margin expansion continues. As low-margin Mixtard rolls off, own brands (gross margin already 46.7%) form a larger share; Q1 FY2027 EBITDA margin of 28.8% versus 25.6% a year earlier is evidence.

  2. Two new growth vectors. Extensior and Awiqli give Abbott India exposure to the fastest-growing therapy in the IPM (anti-diabetics +17.6%), with Novo bearing development and manufacturing.

  3. Capital return and optionality. ₹2,250–4,410 Cr of cash, zero debt and ~90% payout support a ~2.5% yield, with explicit appetite for in-licensing/M&A.

Bear case

  1. Structural growth gap. Reported revenue grew 4.3% in Q1 FY2027 while the IPM grew ~14%; if core brands only match the market, the insulin roll-off caps top-line growth near mid-single digits for several quarters.

  2. GLP-1 economics may disappoint. Extensior launched into semaglutide genericisation; pricing could compress rapidly, and Abbott is a distributor, not owner.

  3. Cost reinvestment and governance flux. Employee costs rose 13.8% in FY2026; 2026 saw a new MD (2025), new Chairman, multiple board changes and a CS exit — execution risk during a portfolio transition.

Catalysts and monitorables (next 12 months)

ItemTiming
Q2 FY2027 results (revenue growth vs IPM ~14.7% in the quarter)By 14 Nov 2026
New Company Secretary appointmentAround 28 Oct 2026
Extensior and Awiqli monthly offtake (Pharmarack/IQVIA)Monthly
Mixtard residual sales and final exit timingOngoing
Independent-director succession (Chairman's second ID term ends ~31 Mar 2027)Q4 FY2027
Q3 FY2027 results; IPM CY2026 exit growthFeb 2027
FY2027 results and dividend (payout level vs FY2026's ~90%)May 2027
Any in-licensing or acquisition using cashEvent-driven
NLEM/DPCO revisions affecting Thyronorm, Mixtard-type molecules, vaccinesEvent-driven

Analyst verdict

Abbott India remains one of the highest-quality franchises in Indian pharma on every balance-sheet and return metric: zero financial debt, roughly 35% ROE, cash conversion above 85% of earnings over five years, and dominant positions in thyroid, hepatoprotection, laxatives, antacids and vertigo. The five-year record — revenue up ~9% a year, profit up ~18% a year — is a story of disciplined operating leverage and portfolio mix rather than volume heroics.

The debate has shifted from quality to growth. FY2026 revenue rose only 8.1% and Q1 FY2027 just 4.3%, precisely when the Indian market accelerated to double digits. The proximate cause is clear and largely exogenous: Novo Nordisk's withdrawal of Human Mixtard, a top-five IPM brand distributed by Abbott India. That roll-off depresses reported sales but flatters margins, which is why profit growth (+17% in Q1) is diverging from the top line. Underlying own-brand growth of ~10% (Pharmarack MAT July 2026) appears healthy but not outstanding against a 13% market.

The 2026 partnerships — Extensior and Awiqli — show that Novo still regards Abbott India as its preferred access partner, and they offer genuine optionality in diabetes. However, Abbott's role is that of a distributor, and the GLP-1 entry coincides with semaglutide genericisation, so these are unlikely to restore double-digit growth by themselves within twelve months.

At ~34x trailing earnings and ~23x EV/EBITDA, the stock has de-rated by roughly a quarter from its historic multiple and now trades near its 52-week low with a ~2.5% yield. The Q2 FY2027 print versus a ~15% IPM quarter is the key near-term test.


Source list (principal): Abbott India Annual Report 2025-26 (abbott.co.in); Statement of Audited Financial Results, quarter and year ended 31 March 2026 (abbott.co.in); Q1 FY2027 unaudited results and board outcome (BSE, 12 Aug 2026); Abbott/Novo Nordisk Extensior press release and BSE intimation (27 Feb 2026); BSE/NSE disclosures on directors, KMP and CS (2025–26); BOB Capital Markets research (29 Apr 2025, 4 Jul 2025, 12 Feb 2026, 13 May 2026, 13 Jul 2026, 3 Sep 2026); ICICI Securities result updates (8 Nov 2025, 13 Feb 2026); Pharmarack/Equirus/PharmaTrac IPM reports (Jan–Oct 2026); Novo Nordisk India Awiqli launch coverage (Reuters via Medical Dialogues, BioSpectrum, Jul 2026); Business Standard and exchange aggregators for shareholding and prices (Oct 2026); stockanalysis.com and screener.in for balance-sheet and cash-flow line items; GSK Pharmaceuticals, Pfizer Ltd, Sanofi India and Mankind Pharma results filings/coverage (2026); Indian Pharma Post (Chairman appointment, Aug 2026); The Print/Medical Dialogues (NPPA overcharging, 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleSinceBackgroundNotes

Dr. Sudarshan Jain (DIN 00927487)

Chairman, Independent Director

ID since 2019; Chairman from 13 Aug 2026

40+ years in pharma; formerly Director-Marketing at Abbott India and GM, Healthcare Solutions at Abbott Healthcare; Secretary-General, Indian Pharmaceutical Alliance

Second ID term began 1 Apr 2022 (ends 31 Mar 2027 by five-year arithmetic) — a near-term succession item

Kartik Rajendran (DIN 09527717)

Managing Director

14 Jun 2025 (to 13 Jun 2030)

20+ years; MBA, Indian School of Business; BA English Literature, Delhi University; previously Regional Head, Abbott SE Asia pharma; GM Specialty Care, Commercial Director Hospital Business, India Head New Products at Abbott Healthcare; ~6 years at McKinsey

Age reported as 47 (GlobalData)

Kaiyomarz Marfatia (DIN 03449627)

Non-Executive Director

Long-serving (former Whole-time Director)

Abbott India veteran

—

Shalini Kamath (DIN 06993314)

Independent Director

———

Vivek Mohan (DIN 00075006)

Non-Executive Director

1 Jan 2026

——

Darshan Gada (DIN 08174581)

Non-Executive Director

18 Aug 2025

——

James Wenner (DIN 11650998)

Non-Executive Director

23 Apr 2026

Vice President & Treasurer, Abbott Laboratories, USA

Confirmed via postal ballot (results due by 18 Jun 2026)

Neeraj Jain (DIN 00348591)

Independent Director

25 Apr 2026

Chartered accountant; 30+ years incl. Johnson & Johnson, Hindustan Unilever

Three-year term

Board of Directors — Kartik Rajendran

NameTitleNotes

Kartik Rajendran

Managing Director

See above

Maithilee Mistry

Chief Financial Officer

KMP from 6 May 2025

Sangeeta Shetty

Company Secretary & Compliance Officer

Resigns effective 28 Oct 2026; successor not yet announced in sources reviewed

Devesh Choudhari

Director, Finance

—

Harshraj Madan

Commercial Director, Gastrointestinal

—

Prithwish Banerji

Commercial Director, Women's Health, Metabolics & International Business

—

Anuj Mehra

Commercial Director, CNS, Multi-Specialty & Vaccines

—

Dr. Jejoe Karankumar

Director, Medical Affairs

—

Vinutha Mufti

Director, Business HR

From 16 Dec 2025

Anushree Kunhambu

Associate Director, New Product Introduction & Therapy Strategy

From 1 Aug 2025

Richa Tripathi

Associate Director, Sales Force Effectiveness & PMO

—

Amol Metkar

Plant Director, Goa

From 1 Jun 2026; ex-Lupin, Sanofi, Cipla, Ranbaxy

Major Shareholders

Holder categoryStake (%)

Promoter group (Abbott Laboratories entities)

74.99

UTI Mutual Fund (schemes)

7.55

Insurance companies

1.25

Foreign institutional investors

0.40

Non-institutional investors

2.44

Indian public (individuals)

13.19

Competitive Landscape

Competitor Detail

TherapyKey competitors (named)Abbott positioning

Gastrointestinal

Sun Pharma, Alkem (Pan, Pan-D), Torrent, Dr. Reddy's, Mankind, Zydus, Cipla

#4 in GI; #1 hepatoprotectives (Udiliv); leadership in laxatives, antacids, enzymes, prokinetics

Thyroid / Hormones

Merck/Macleods (Thyrox), GSK (Eltroxin), Mankind, Intas

#1 (Thyronorm, ~56% share)

Diabetes / GLP-1 / insulin

Novo Nordisk (direct), Eli Lilly (Mounjaro; Cipla partnership), Sanofi (Lantus, Toujeo, Soliqua), USV (Glycomet), Emcure (Poviztra, Wegovy second brand), Natco/Eris, Biocon, Lupin, Dr. Reddy's (semaglutide generics)

Distributor of Novo brands; new GLP-1 entrant via Extensior

Women's Health

Sun Pharma, Mankind, Zydus, Intas, Lupin, generic dydrogesterone players

#4 in gynaecology; Duphaston leader in dydrogesterone

CNS

Sun Pharma, Torrent, Intas, Lupin, Cipla (vertigo: Stugeron-class/betahistine generics)

#4 in CNS; Vertin leader in vertigo

Vaccines

Sanofi, GSK, Serum Institute, Zydus, Bharat Biotech, MSD, Pfizer

#4 in vaccines; Influvac key adult flu brand

Multi-Specialty

Mankind, Alkem, Sun, Cadila (vitamin D: Calcirol etc.)

Arachitol nano differentiation

Peer Comparison FY2026

MetricAbbott IndiaGSK Pharmaceuticals (India)Pfizer Ltd (India)Mankind Pharma

Fiscal year

FY2026 (Mar)

FY2026 (Mar), consolidated

FY2026 (Mar)

FY2026 (Mar), consolidated

Revenue (INR Cr)

6,9293,8222,52014,278

Revenue growth (%)

8.11.910.417.0

EBITDA/OPM margin (%)

27.3 (excl. OI)

34.3

35.9 (computed, operating profit ₹904 Cr)

25.4 (adjusted)

Net profit (INR Cr)

1,5521,036722

≈1913 (computed at 13.4% margin)

Net margin (%)

22.427.128.713.4

R&D intensity

Not disclosed (minimal)

Not disclosed (minimal)

Not disclosed (minimal)

—

Dividend per share FY2026 (INR)

6565775—

Company Snapshot

$800.1M

Revenue

3,679

Employees

1944

Founded

SWOT Analysis

Strengths

  • Dominant brands: 7 brands in IPM top 100 and 10 in top 300; #1 in hepatoprotectives and hormones (IQVIA MAT Mar 2026, AR FY2026).
  • Brand scale: Udiliv crossed ₹700 Cr and Thyronorm ≈₹716 Cr MAT with ~52–56% shares; Ganaton became the seventh GI brand above ₹100 Cr (AR FY2026; ICICI).
  • Profitability: EBITDA margin (company definition) rose from 23.7% (FY2022) to 31.5% (FY2026); net margin 22.4% (AR).
  • Returns: ROE ~34–36% for three consecutive years with zero bank debt (AR).
  • Cash generation: five-year cumulative FCF ≈₹5,165 Cr; capex <1% of sales (computed from filings).
  • Partner of choice: Novo Nordisk chose Abbott India for Extensior and Awiqli in 2026, validating distribution reach (company press release; media).
  • Talent depth: all FY2026 leadership appointments filled internally; attrition declined (AR).

Weaknesses

  • Top-line deceleration: revenue growth slowed to 8.1% (FY2026) and 4.3% (Q1 FY2027) versus IPM growth of 13–15% in mid-2026.
  • Licensor dependence: Human Mixtard (≈₹795 Cr MAT Jan 2026) is being withdrawn by Novo, not by Abbott's choice.
  • No R&D pipeline: innovation limited to formats and in-licensing; R&D spend not material/disclosed.
  • Concentration: gastro ≈46% of secondary sales (Pharmarack MAT Jul 2026); top-10 brands dominate.
  • Rising working capital: inventory days increased from 78.3 to 90.4 in FY2026 (AR).
  • Thin float and liquidity: promoter holding 74.99%; daily volumes often a few thousand shares.

Opportunities

  • GLP-1 wave: Extensior entry into India's fastest-growing therapy (anti-diabetics +17.6% in July 2026; Mounjaro scaled rapidly).
  • Weekly insulin: Awiqli at ₹261/week undercuts daily basal insulin (₹345–453 per 70 units) — conversion potential among ~6 million insulin users, expected to reach 9 million (Novo India).
  • Adult vaccination: vaccines grew 16.7% (MAT Jan 2026, Pharmarack); Abbott ranks #4.
  • Liver disease (MASLD/MASH): natural adjacency for Udiliv/Heptral franchise (AR strategy).
  • Cash for in-licensing/M&A: ₹2,250–4,410 Cr cash/deposits (definition-dependent) with explicit "build and partner" mandate.
  • IPM acceleration: IPM MAT growth improved to 13.2% (Sep 2026) with volume becoming the largest contributor (Equirus).

Threats

  • Semaglutide genericisation: 7–8 generic brands expected post-March 2026 LoE could compress GLP-1 pricing and Extensior economics.
  • Price regulation: NPPA oversight; industry overcharging demands of ₹8,526 Cr unpaid as of Sep 2025 signal enforcement intensity.
  • Generic erosion: dydrogesterone generics and flu-vaccine pricing pressure cited in AR FY2026.
  • Labour-cost inflation: Labour Codes added ₹18.10 Cr in FY2026; employee costs +13.8%.
  • Competitive in-licensing: Lilly–Cipla, Novo–Emcure, Natco–Eris deals intensify partner competition.
  • Valuation de-rating: stock down ~12% over one year and at the low end of its 52-week range despite earnings growth.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Novo Nordisk to discontinue Human Mixtard and older insulins in IndiaRemoves a top-5 IPM brand from Abbott India's distributed portfolio; top-line headwind, margin tailwind
6 May 2025Maithilee Mistry appointed KMP (CFO)Finance leadership
7 May 2025MD Swati Dalal resigns; Kartik Rajendran named MD from 14 Jun 2025CEO transition
15 May 2025FY2025 results: revenue ₹6,409 Cr (+9.6%), PAT ₹1,414 Cr (+17.8%); dividend ₹475Margin expansion story intact
25 Jul 2025Record date for ₹475 final dividend—
12 Aug 2025Q1 FY2026: revenue ₹1,738 Cr; PAT ₹366 Cr—
18 Aug 2025Darshan Gada appointed NEDBoard refresh
17 Sep 2025One Abbott blood donation drive (1,143 units)ESG
6 Nov 2025Q2 FY2026: revenue ₹1,757 Cr (+7.6%); PAT ₹415 Cr (+15.8%)Margin-led growth
21 Nov 2025Labour Codes notified₹18.10 Cr FY2026 cost
24 Nov 2025Central Government approves MD appointmentRegulatory formality
16 Dec 2025Vinutha Mufti named Director, Business HR—
1 Jan 2026Vivek Mohan appointed NEDBoard refresh
12 Feb 2026Q3 FY2026: revenue ≈₹1,724 Cr; reported EBITDA margin 26.9% (adjusted ~28.9% per BOB) amid higher employee costsGLP-1 preparation
13 Feb 2026ICICI Securities BUY, TP ₹32,150 ("slowdown in Novo portfolio")Sell-side view
27 Feb 2026Extensior partnership with Novo NordiskGLP-1 entry
Mar 2026Semaglutide patent expiry in India; generic wave (Natco/Eris and others)Competitive pressure on Extensior/Rybelsus pricing
22–25 Apr 2026Board changes: Davies resigns; Motwani term ends; Wenner and N. Jain appointedGovernance refresh
11 May 2026FY2026 results; ₹656 dividend (incl. ₹131 special); Munir Shaikh not seeking reappointment; a brokerage "double downgrade" reported the same day (broker not identified in sources)Slowing growth narrative
13 May 2026Postal ballot notice for Wenner/N. Jain; BOB Capital BUY, TP ₹36,457—
1 Jun 2026Amol Metkar becomes Goa Plant DirectorOperations
1–9 Jul 2026Large NSE block trades (₹25.6 Cr and ₹20.5 Cr)Liquidity events
10 Jul 2026Awiqli launched in India by NovoNew distributed product
13 Jul 2026BOB update: monthly sales back to double digits; IPM CY2026 forecast raised to 11.3%Demand acceleration
20 Jul 2026Annual Report FY2025-26 and assured BRSR filedDisclosure
12 Aug 2026Q1 FY2027: revenue +4.3%, PAT +17.1%, EBITDA margin 28.8%; Sudarshan Jain named ChairmanMargin-led beat; low top-line growth
13 Aug 202682nd AGM; ICICI Securities TP ₹32,210 (per secondary report); Awiqli distribution role reported—
18 Aug 2026FY2026 dividend payout commences≈₹1,394 Cr cash return
3 Sep 2026BOB: core portfolio growing at par with IPM (MAT Jul'26 +10%)—
7 Sep 2026CS Sangeeta Shetty resigns (effective 28 Oct 2026)Compliance continuity
11 Sep 202652-week low (~₹25,135)Valuation de-rating
20 Sep 2026Added to S&P Global BMIPassive flows
1 Oct 2026Trading window closed ahead of Q2 FY2027 results—
15 Oct 2026IPM grew 17.1% in Sep 2026 and 14.7% in Q2 FY2027 (Equirus)Raises the bar for Abbott's Q2 print

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 49,130 Mn in FY2022 to INR 69,290 Mn in FY2026.
Abbott India Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations49,13053,49058,49064,09069,290
Gross profit22,56023,74026,29029,12032,360

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.